
Pancreatic Cancer - Pipeline Insight, 2022
Description
Pancreatic Cancer - Pipeline Insight, 2022
DelveInsight’s, “Pancreatic Cancer - Pipeline Insight, 2022,” report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in Pancreatic Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Pancreatic Cancer: Overview
Pancreatic cancer refers to the carcinoma arising from the pancreatic duct cells, pancreatic ductal carcinoma. It is the fourth leading cause of cancer deaths in the United States. The 5-year survival rate in the United States ranges from 5% to 15%. The overall survival rate is only 6%. Surgical resection is the only current option for a cure, but only 20% of pancreatic cancer is surgically resectable at the time of diagnosis. More than 90% of adenocarcinoma of the pancreas are duct cell adenocarcinomas with other types being cystadenocarcinoma and acinar cell carcinoma. Two-thirds arise in the pancreatic head; one-third arise in the rest (body and tail of pancreas). Patients with adenocarcinoma of pancreas typically present with painless jaundice (70%) usually due to obstruction of the common bile duct from the pancreatic head tumor. Weight loss occurs in about 90% of patients. Abdominal pain occurs in about 75% of patients. Weakness, pruritus from bile salts in the skin, anorexia, palpable, non-tender, distended gallbladder, acholic stools, and dark urine. Sometimes, patients may present with recurrent deep vein thrombosis (DVT) due to hypercoagulability that prompts clinicians to suspect cancer and a full workup of cancer. If adenocarcinoma of the pancreas is suspected, multidetector computed tomography, MDCT, is the best imaging modality to diagnose and evaluate the extent of disease, including perivascular extension and distant metastasis. MDCT is 77% accurate in predicting resectability and 93% accurate in predicting unresectability.
""Pancreatic Cancer - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pancreatic Cancer pipeline landscape is provided which includes the disease overview and Pancreatic Cancer treatment guidelines. The assessment part of the report embraces, in depth Pancreatic Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pancreatic Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Pancreatic Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Pancreatic Cancer Emerging Drugs
Further product details are provided in the report……..
Pancreatic Cancer: Therapeutic Assessment
This segment of the report provides insights about the different Pancreatic Cancer drugs segregated based on following parameters that define the scope of the report, such as:
Pancreatic Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pancreatic Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pancreatic Cancer drugs.
Pancreatic Cancer Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Pancreatic Cancer - Pipeline Insight, 2022,” report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in Pancreatic Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Pancreatic Cancer: Overview
Pancreatic cancer refers to the carcinoma arising from the pancreatic duct cells, pancreatic ductal carcinoma. It is the fourth leading cause of cancer deaths in the United States. The 5-year survival rate in the United States ranges from 5% to 15%. The overall survival rate is only 6%. Surgical resection is the only current option for a cure, but only 20% of pancreatic cancer is surgically resectable at the time of diagnosis. More than 90% of adenocarcinoma of the pancreas are duct cell adenocarcinomas with other types being cystadenocarcinoma and acinar cell carcinoma. Two-thirds arise in the pancreatic head; one-third arise in the rest (body and tail of pancreas). Patients with adenocarcinoma of pancreas typically present with painless jaundice (70%) usually due to obstruction of the common bile duct from the pancreatic head tumor. Weight loss occurs in about 90% of patients. Abdominal pain occurs in about 75% of patients. Weakness, pruritus from bile salts in the skin, anorexia, palpable, non-tender, distended gallbladder, acholic stools, and dark urine. Sometimes, patients may present with recurrent deep vein thrombosis (DVT) due to hypercoagulability that prompts clinicians to suspect cancer and a full workup of cancer. If adenocarcinoma of the pancreas is suspected, multidetector computed tomography, MDCT, is the best imaging modality to diagnose and evaluate the extent of disease, including perivascular extension and distant metastasis. MDCT is 77% accurate in predicting resectability and 93% accurate in predicting unresectability.
""Pancreatic Cancer - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pancreatic Cancer pipeline landscape is provided which includes the disease overview and Pancreatic Cancer treatment guidelines. The assessment part of the report embraces, in depth Pancreatic Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pancreatic Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Pancreatic Cancer.
- In the coming years, the Pancreatic Cancer market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics that are working to assess challenges and seek opportunities that could influence Pancreatic Cancer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- A detailed portfolio of major pharma players who are involved in fueling the Pancreatic Cancer treatment market. Several potential therapies for Pancreatic Cancer are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Pancreatic Cancer market size in the coming years.
- Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Pancreatic Cancer) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
This segment of the Pancreatic Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Pancreatic Cancer Emerging Drugs
- Pamrevlumab: FibroGen
- Niraparib: Innovent Biologics
- CT041: CARsgen Therapeutics
- APG-1387: Ascentage Pharma
- NGM120: NGM Biopharmaceuticals
Further product details are provided in the report……..
Pancreatic Cancer: Therapeutic Assessment
This segment of the report provides insights about the different Pancreatic Cancer drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Pancreatic Cancer
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Inhalation
- Inhalation/Intravenous/Oral
- Intranasal
- Intravenous
- Intravenous/ Subcutaneous
- NA
- Oral
- Oral/intranasal/subcutaneous
- Parenteral
- Subcutaneous
- Molecule Type
- Antibody
- Antisense oligonucleotides
- Immunotherapy
- Monoclonal antibody
- Peptides
- Protein
- Recombinant protein
- Small molecule
- Stem Cell
- Vaccine
- Product Type
Pancreatic Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pancreatic Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pancreatic Cancer drugs.
Pancreatic Cancer Report Insights
- Pancreatic Cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Pancreatic Cancer drugs?
- How many Pancreatic Cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pancreatic Cancer?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Pancreatic Cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Pancreatic Cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
- FibroGen
- Innovent Biologics
- CARsgen Therapeutics
- Ascentage Pharma
- NGM Biopharmaceuticals
- TME Pharma AG
- Lee's Pharmaceutical Limited
- ImmunityBio, Inc.
- Rgene Corporation
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- CanBas Co. Ltd.
- Jiangsu HengRui Medicine Co., Ltd.
- Bristol-Myers Squibb
- SynerGene Therapeutics, Inc.
- AbbVie
- Silenseed Ltd
- Galera Therapeutics, Inc.
- Helix BioPharma
- Golden Biotechnology Corporation
- Eli Lilly and Company
- Innovent Biologics (Suzhou) Co. Ltd.
- Panbela Therapeutics, Inc.
- GlaxoSmithKline
- Chia Tai Tianqing Pharmaceutical Group
- Roche
- Prestige Biopharma Limited
- Everfront Biotech Co., Ltd.
- XBiotech, Inc.
- Incyte Corporation
- Ability Pharmaceuticals SL
- Lokon Pharma
- HCW Biologics
- Amplia Therapeutics Limited
- BioLineRx, Ltd.
- Taiho Pharmaceutical
- Sanofi
- Scandion Oncology
- Nelum
- Celldex Therapeutics
- Merus N.V.
- Seagen Inc.
- GC Cell Corporation
- MetiMedi Pharmaceuticals
- Lumicell
- Nuvation Bio Inc.
- ENB Therapeutics
- BioNTech SE
- Pamrevlumab
- Niraparib
- CT041
- APG-1387
- BNT141
- ENB003
- NUV-868
- MCLA-128
- LUM015
- Immuncell-LC
- tisotumab vedotin
- OMT-111
- tusamitamab ravtansine
- SCO-101
- NGM120
- CDX-301
- NLM-001
- TAS 102
- Olaptesed pegol
- BL-8040
- Gimatecan
- AMP945
- N-803
- HCW9218
- BLEX 404
- delolimogene mupadenorepvec
- Mitoxantrone Hydrochloride Liposome injection
- ABTL0812
- CBP501
- Pemigatinib
- SHR-1701
- Fluzoparib
- XB2001
- Cabiralizumab
- EF-009
- SGT-53
- ABBV-927
- PBP1510
- Vemurafenib
- siG12D-LODER
- Penpulimab
- GC4711
- GSK2256098
- L-DOS47
- SBP-101
- Antroquinonol
- LY3214996
- Sintilimab
Table of Contents
300 Pages
- Introduction
- Executive Summary
- Pancreatic Cancer: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Pancreatic Cancer – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Pamrevlumab: FibroGen
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Niraparib: Innovent Biologics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Comparative Analysis
- CT041: CARsgen Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- ONC 212: Oncoceutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Pancreatic Cancer Key Companies
- Pancreatic Cancer Key Products
- Pancreatic Cancer- Unmet Needs
- Pancreatic Cancer- Market Drivers and Barriers
- Pancreatic Cancer- Future Perspectives and Conclusion
- Pancreatic Cancer Analyst Views
- Pancreatic Cancer Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.